Post-exercise abdominal, subcutaneous adipose tissue lipolysis in fasting subjects is inhibited by infusion of the somatostatin analogue octreotide.
To determine whether blockade of the exercise-induced increase in growth hormone (GH) secretion may affect the regional lipolytic rate in the post-exercise recovery period, the aim of the present experiments was to study the effect of infusion of the somatostatin analogue octreotide on the s.c., abdominal adipose tissue metabolism, before, during and after exercise in healthy, fasting, young male subjects. The adipose tissue net releases of fatty acids and glycerol were measured by arterio-venous catheterizations and simultaneous measurements of adipose tissue blood flow with the local Xe-clearance method. Nine subjects were studied during 1-h basal rest, and then during continuous octreotide infusion during 1-h rest, 1-h exercise at 50% of maximal oxygen consumption and 4-h post-exercise rest. A control study on seven subjects was performed under similar conditions but without octreotide infusion. The results show that octreotide infusion during rest increased lipolysis and fatty acid release from the abdominal, s.c. adipose tissue. The exercise-induced increase in lipolysis and fatty acid release does not seem to be affected by octreotide when compared with the control study without octreotide infusion while the post-exercise increase in lipolysis is inhibited by octreotide, suggesting that the exercise-induced increase in GH secretion plays a role for the post-exercise lipolysis in s.c., abdominal adipose tissue.
Enevoldsen
Lotte H
LH
Department of Clinical Physiology, Bispebjerg Hospital, Bispebjerg Bakke 23, DK-2400 Copenhagen NV, Denmark.
Polak
Jan
J
Simonsen
Lene
L
Hammer
Troels
T
Macdonald
Ian
I
Crampes
Francois
F
de Glisezinski
Isabelle
I
Stich
Vladimir
V
Bülow
Jens
J
D000328:Adult; D001783:Blood Flow Velocity; D001786:Blood Glucose / Q000378:metabolism; D002395:Catecholamines / Q000097:blood; D015444:Exercise / Q000502:physiology*; D005215:Fasting / Q000378:metabolism*; D005227:Fatty Acids / Q000097:blood; D005990:Glycerol / Q000097:blood; D006727:Hormone Antagonists / Q000008:administration & dosage*; D019382:Human Growth Hormone / Q000037:antagonists & inhibitors* / Q000097:blood; D006801:Humans; D007262:Infusions, Intravenous; D007328:Insulin / Q000097:blood; D008066:Lipolysis / Q000187:drug effects*; D008297:Male; D015282:Octreotide / Q000008:administration & dosage*; D010101:Oxygen Consumption; D012123:Pulmonary Ventilation; D012039:Regional Blood Flow; D050507:Subcutaneous Fat, Abdominal / Q000098:blood supply / Q000187:drug effects* / Q000378:metabolism; D013997:Time Factors
D001786:Blood Glucose; D002395:Catecholamines; D005227:Fatty Acids; D006727:Hormone Antagonists; D007328:Insulin; D019382:Human Growth Hormone; D005990:Glycerol; D015282:Octreotide